Evaluation of Richmond Agitation Sedation Scale According to Alveolar Concentration of Sevoflurane During a Sedation With Sevoflurane in ICU Patients (SEVORASS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02202720|
Recruitment Status : Completed
First Posted : July 29, 2014
Last Update Posted : November 26, 2014
|Condition or disease||Intervention/treatment||Phase|
|Requiring Sedation by Sevoflurane in ICU Adult Patients Patients Covered by French Health Care System Patients Who Have Given Their Consent||Drug: Sevoflurane||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Richmond Agitation Sedation Scale According to Alveolar Concentration of Sevoflurane During a Sedation With Sevoflurane in ICU Patients|
|Study Start Date :||August 2014|
|Actual Primary Completion Date :||November 2014|
|Actual Study Completion Date :||November 2014|
Short term sedation with sevoflurane in ICU
- Description of the RASS score [ Time Frame: at day 1 ]Describe the RASS score corresponding to the values of sevoflurane MAC during sedation of patients in ICU : RASS score determined at the middle of each level of 30 minutes, each level correspond to determined sevoflurane MAC with ascending MAC ranging from 0 to 0.8 and then descending MAC from 0.8 to 0.
- determination of the associated hemodynamic and respiratory parameters [ Time Frame: at day 1 ]Determine the associated hemodynamic and respiratory parameters, bispectral index and analgesia-nociception index for each level of sevoflurane MAC (monitored at the middle of each level of 30 minutes).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02202720
|Clermont-Ferrand, France, 63003|
|Principal Investigator:||Sébastien PERBET||University Hospital, Clermont-Ferrand|